Is the post-earnings rally in this struggling life sciences stock for real this time?

Danaher (DHR) reported better-than-expected Q2 earnings and raised its full-year EPS guidance, sparking a 10% stock rally, with all three operating segments beating estimates and bioprocessing showing strong long-term growth. However, significant headwinds persist, including a mid-single-digit sales decline in China and a projected $150 million adverse impact from volume-based procurement in diagnostics for 2025. Management maintained its full-year adjusted core revenue growth outlook at approximately 3% due to caution, and analysts suggest a sustained sector rally requires a return to mid-single-digit revenue growth, which remains a quarter or two away.

Analysis

Danaher Corporation (DHR) reported a better-than-expected second quarter, with beats on both earnings per share and revenue across all three of its operating segments, sparking a 10% post-earnings rally. The company raised its full-year EPS guidance, and management expressed confidence in a high single-digit, long-term growth outlook for its bioprocessing segment. However, this positive operational performance is tempered by significant headwinds and a cautious forward-looking stance. Management maintained its full-year adjusted core revenue growth outlook at approximately 3%, citing uncertainty. The primary drag remains China, which constitutes 12% of total revenue and experienced a mid-single-digit sales decline in Q2. Specifically, the diagnostics business in China is pressured by the country's Volume-Based Procurement (VBP) policy, which is projected to have a $150 million adverse impact in 2025. Analyst commentary from RBC echoes this caution, suggesting a sustained sector-wide rally is unlikely until mid-single-digit revenue growth returns, an event they forecast is still one or two quarters away. While management's guidance may prove conservative—as it excludes the potential continuation of favorable currency effects and respiratory business strength from the first half—the unresolved issues in China prevent a definitive call on a bottom for the stock.

Key Decisions for Investors

• Investors should monitor for a return to mid-single-digit core revenue growth, which analysts identify as the key catalyst for a sustained stock rally and is not expected for another one to two quarters.
• The primary risk to monitor is performance in China, particularly the impact of the Volume-Based Procurement (VBP) policy, which management has quantified as a $150 million headwind for 2025.
• Consider that current full-year revenue guidance could be conservative, as management has not extrapolated certain favorable first-half trends, presenting potential for upside if the operating environment remains stable.